Search

Search bills, members, committees and pages...

H.Res. 342

U.S. HouseIn House Committee

Summary

H.Res. 342, “Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes”, was introduced in the House on Apr 21, 2025 by Rep. James McGovern (D). It was referred to Energy And Commerce, and last saw action on Apr 21, 2025: Referred to the House Committee on Energy and Commerce.


Record

Text

H.Res. 342 has no co-sponsors and has not gone to a roll call.

hres342/introduced-in-house.txt
119 HRES 342 IH: Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes.
U.S. House of Representatives
2025-04-21
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
IV 119th CONGRESS 1st Session H. RES. 342 IN THE HOUSE OF REPRESENTATIVES April 21, 2025 Mr. McGovern submitted the following resolution; which was referred to the Committee on Energy and Commerce RESOLUTION
Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes.
Whereas diethylstilbestrol ( DES ) is a toxic and carcinogenic estrogen and endocrine disrupter;
Whereas the Food and Drug Administration ( FDA ) approved DES in the early 1940s;
Whereas DES was widely prescribed, with the intention of preventing miscarriage, to between five and ten million pregnant women in the United States until 1971;
Whereas DES exposure in utero was linked to the development of rare cancers of the vagina and cervix called clear cell adenocarcinoma in female children, commonly referred to as DES Daughters ;
Whereas the FDA banned the use of DES during pregnancy in the United States in 1971;
Whereas DES exposure in utero has since been linked to increased fertility and pregnancy complications and other physical and mental health challenges;
Whereas the FDA has acknowledged the harm caused by DES but has yet to apologize to the families of those impacted by its prolonged use; and
Whereas April 20 through 26, 2025, would be an appropriate week to designate as DES Awareness Week : Now, therefore, be it
That the House of Representatives—
(1)
expresses support for the designation of DES Awareness Week ;
(2)
recognizes the history of the drug diethylstilbestrol and the harm it has caused;
(3)
supports the restoration of funding for the DES Follow-Up Study; and
(4)
urges the Food and Drug Administration to issue a formal apology to families impacted by diethylstilbestrol.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-04-21
  2. Passed House

Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes.

Sponsors

Rep. James McGovern (D) sponsors H.Res. 342 alone.

Committees

H.Res. 342 went before 1 committee: Energy and Commerce.

Energy and Commerce
Energy and Commerce
Referred To · Apr 21, 2025 · 1,636 Bills

Actions

H.Res. 342 has taken 2 actions since Apr 21, 2025.

ChamberAction
Apr 21, 2025
House
Submitted in House
Apr 21, 2025
House
Referred to the House Committee on Energy and Commerce.Energy and Commerce Committee

Votes

H.Res. 342 has not gone to a roll call.

Titles

H.Res. 342 goes by 2 titles.

  • Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes. — Official Title as Introduced
  • Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes. — Display Title

Classification

The Congressional Research Service files H.Res. 342 under Health, one of its 31 policy areas, and gives it 8 legislative subjects.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.Res. 342’s is Health.

hres342/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Legislative Subjects

H.Res. 342 carries 8 of CRS’s legislative subjects, from Cancer to Women's health.

hres342/subjects.txt
CancerDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Medical researchPrescription drugsResearch administration and fundingSex and reproductive healthWomen's health

Source: congress.gov · legiscan.com